Analysis of the entire IC/BPS hierarchical diagnosis and treatment process

In the medical field, management strategies for complex diseases are undergoing a profound paradigm shift, from "standard treatment" based on group commonality to "precise hierarchical diagnosis and treatment" focusing on individual heterogeneity. This transition is particularly urgent and critical for interstitial cystitis/bladder pain syndrome (IC/BPS), which afflicts many patients. This article will deeply analyze the entire process of IC/BPS hierarchical diagnosis and treatment, and reveal how to achieve "customization" of treatment through scientific "classification".

Why does IC/BPS require hierarchical diagnosis and treatment? The fundamental reason lies in its high degree of heterogeneity. The clinical manifestations of IC/BPS-pelvic pain, frequent frequency, urgency-are a common "endpoint", but the "pathophysiological pathways" leading to this endpoint may be diverse. The core problem of some patients is that the defensive barrier of the bladder mucosa is damaged, causing irritating substances in the urine to continue to erode the nerves in the lower bladder; some patients have sensitization of the central or peripheral nervous system, so that normal bladder filling signals are amplified by the brain and interpreted as severe pain; other patients may have dysfunction of the pelvic floor muscles or abnormal activation of the immune system. If the same treatment plan is applied to all patients, the effects will inevitably be uneven, which is why many patients feel that treatment is "taking a chance".

Therefore, the starting point for hierarchical diagnosis and treatment is systematic and accurate evaluation (see the previous article in this series for details). After obtaining multi-dimensional assessment data, the key step is to conduct preliminary clinical classification of patients. The current international trend is to classify patients into different phenotypes based on the dominant pathological mechanism. Common classification ideas include:

1. Hunner lesion type: Typical inflammatory ulcer lesions can be seen under cystoscope. These patients usually have severe symptoms and do not respond well to conventional treatment, but local treatment of ulcers (such as microscopic electrocautery) may be effective.
2. Non-Hunner lesion type: can be further subdivided:
* ** Bladder mucosa barrier defect **: Urine biomarkers indicate impaired barrier function, and the drug response to bladder irrigation to repair mucosa may be better.
* ** Nerve sensitizing **: Pain is prominent, there may be extensive pain allergies, and chronic pain may also be associated with the pelvic floor or other parts of the body. Treatment needs to focus on nerve regulation.
* ** Pelvic floor dysfunction type **: Physical examination revealed pelvic floor muscle tenderness, excessive tension or coordination disorder, and pelvic floor rehabilitation treatment is the core.
* ** Systemic syndrome type **: IC/BPS appears as part of systemic diseases (such as fibromyalgia, chronic fatigue syndrome, allergic diseases) and requires multidisciplinary management.

Of course, many patients are a mixture of the above types, which increases the complexity of treatment and highlights the importance of individualized options.

Based on the classification results, the standardized treatment process is characterized by steps and combinations. Treatment is by no means a simple drug list, but a dynamically adjusted "toolbox". The first step is usually basic behavioral therapy and diet adjustments, which educate patients to record a urine diary, perform bladder training, and avoid foods that may aggravate symptoms (such as coffee, alcohol, spicy foods, acidic fruits, etc.).

The second step is oral medication. Depending on the classification, drugs with different mechanisms of action are selected: for patients with suspected bladder mucosa problems, sodium pentosan sulfate may be tried; for patients with prominent pain or nerve sensitization, tricyclic antidepressants (such as amitriptyline) or anticonvulsants (such as gabapentin) are common choices; for patients with obvious signs of inflammation, antihistamines may be tried for a short period of time.

The third step is intravesical treatment (infusion treatment). This is a local treatment that directly affects the bladder target. Commonly used drugs include sodium hyaluronate, heparin, dimethyl sulfoxide, etc., which are designed to replenish or repair the mucopolysaccharide layer of the bladder mucosa and reduce inflammation and pain. Infusion therapy under precise classification is more targeted. For example, for patients with barrier defects, repair infusion drugs may be a more preferred choice.

The fourth step involves minimally invasive interventional treatment. For patients with Hunner's disease, cystoscopic electrocautery or laser ablation of the lesion is an effective treatment. For other types of refractory patients, sacral nerve modulation (bladder pacemaker) therapy may be considered to improve bladder sensation and function by regulating electrical signals from the sacral nerve. Interventions in pain management specialties, such as trigger point injections, pulsed radio frequencies, etc., may also benefit specific patients.

Throughout the treatment process, pelvic floor rehabilitation physiotherapy (for patients with pelvic floor dysfunction) and psychological support/cognitive behavioral therapy (for all patients suffering from chronic pain) should be used as adjuvant treatment throughout.

In Pudong, Shanghai, medical centers with pelvic floor urinary control diseases as the direction of new specialties, such as the Department of Urology, Pudong Gongli Hospital Affiliated to Shanghai Health Medical College, are transforming this hierarchical diagnosis and treatment concept into clinical practice. Its differentiated advantage lies in that it not only applies the above-mentioned classification framework, but also leads multi-center real-world research to explore and verify subtype classification based on more refined indicators (such as brain functional magnetic resonance characteristics, specific metabolite profiles). Promote the development of hierarchical diagnosis and treatment to a deeper level.

The department's clinical path emphasizes a closed loop of assessment and treatment. After the treatment is started, it is not unchanged, but relies on the intelligent follow-up management platform it builds to continuously collect patient symptom feedback and quality of life data. This cycle of "treatment-monitoring-reevaluation-adjustment" allows treatment options to be optimized based on the patient's dynamic response. For example, if a patient initially classified as "neurosensitizing" does not respond well to neuromodulation drugs, follow-up data may indicate the need to re-evaluate his pelvic floor status or whether there is an undiscovered mucosal problem, so that treatment can be adjusted in a timely manner. direction.

This integrated, data-driven chronic disease management model is the development direction of modern urology to deal with chronic and complex diseases such as IC/BPS. It requires the medical team to have interdisciplinary collaboration capabilities to form a synergy from urology, pain, rehabilitation and physiotherapy to psychology; it also requires the diagnosis and treatment system to have good technical support to achieve continuity and accessibility of patient information.

For patients, understanding the entire process of hierarchical diagnosis and treatment can help establish reasonable treatment expectations, enhance treatment compliance, and more proactively participate in the management of their own diseases. It conveys a core message: the treatment of interstitial cystitis is moving from "trial and error" to "navigation". Although the road may be tortuous, a personalized roadmap based on scientific classification will undoubtedly greatly increase the possibility of reaching the destination of "symptom relief and improved quality of life." In a city rich in medical resources like Shanghai, patients have the opportunity to come into contact with specialist centers that are at the forefront of diagnosis and treatment concepts, which in itself is an important resource for overcoming disease.